Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study evaluates the safety and efficacy of PTX‐022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four‐parts, and if a participant completes all parts, the participant will have received at least 3‐months of PTX‐022 treatment.
Epistemonikos ID: 0f9b28c1df01e9e425036194eb446a7242975ff1
First added on: May 22, 2024